| Escalating to medium‐versus high‐efficacy disease modifying therapy after low‐efficacy treatment in relapsing remitting multiple sclerosis J Müller, I Roos, T Kalincik, J Lorscheider, E Galli, P Benkert, S Schädelin, ... Brain and Behavior 14 (5), e3498, 2024 | | 2024 |
| A Novel Methodology for Developing Smartphone-instrumented Tests for Assessing Movement, Dexterity, and Balance in Neurological Patients: Technical Verification of Ground Truth … AE Bernad, T Woelfle, C Granziera, L Kappos, J Lorscheider, A Barragan, ... Neurology 102 (17_supplement_1), 5218, 2024 | | 2024 |
| Association of spinal cord atrophy and brain paramagnetic rim lesions with progression independent of relapse activity in people with MS A Cagol, P Benkert, L Melie-Garcia, SA Schaedelin, S Leber, C Tsagkas, ... Neurology 102 (1), e207768, 2024 | 7 | 2024 |
| Neurofilament light chain elevation and disability progression in multiple sclerosis A Abdelhak, P Benkert, S Schaedelin, WJ Boscardin, C Cordano, ... JAMA neurology 80 (12), 1317-1325, 2023 | 13 | 2023 |
| Smartwatch-derived sleep and heart rate measures complement step counts in explaining established metrics of MS severity T Woelfle, S Pless, Ó Reyes, A Wiencierz, L Kappos, C Granziera, ... Multiple Sclerosis and Related Disorders 80, 105104, 2023 | 1 | 2023 |
| Comparative analysis of dimethyl fumarate and teriflunomide in relapsing–remitting multiple sclerosis J Müller, S Schädelin, J Lorscheider, P Benkert, P Hänni, J Schmid, ... European Journal of Neurology 30 (12), 3809-3818, 2023 | 1 | 2023 |
| Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: A systematic review J Müller, A Cagol, J Lorscheider, C Tsagkas, P Benkert, Ö Yaldizli, ... JAMA neurology, 2023 | 21 | 2023 |
| Personalized treatment decision algorithms for the clinical implementation of serum neurofilament light chain in multiple sclerosis: a modified Delphi study P Janiaud, P Benkert, L Achtnichts, A Bar-Or, VB Lang, C Bridel, ... MULTIPLE SCLEROSIS JOURNAL 29, 961-963, 2023 | 1 | 2023 |
| Smartwatch-Derived Activity, Sleep, and Heart Rate Measures Correlate with Clinical Measures in Patients with Multiple Sclerosis T Woelfle, S Pless, O Reyes, A Wiencierz, L Kappos, C Granziera, ... MULTIPLE SCLEROSIS JOURNAL 29, 924-924, 2023 | | 2023 |
| Serum glial fibrillary acidic protein (GFAP) is a longitudinal indicator of disease progression in MS while neurofilament light chain (NfL) associates with therapy response in … P Benkert, AM Maceski, S Schadelin, E Willemse, S Meier, L Melie-Garcia, ... MULTIPLE SCLEROSIS JOURNAL 29, 58-60, 2023 | 1 | 2023 |
| Wearable sensor technologies to assess motor functions in people with multiple sclerosis: systematic scoping review and perspective T Woelfle, L Bourguignon, J Lorscheider, L Kappos, Y Naegelin, ... Journal of Medical Internet Research 25, e44428, 2023 | 13 | 2023 |
| Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study S Pless, T Woelfle, Y Naegelin, J Lorscheider, A Wiencierz, Ó Reyes, ... Journal of Neurology 270 (7), 3451-3463, 2023 | 3 | 2023 |
| Recanalization therapies for large vessel occlusion due to cervical artery dissection: a cohort study of the EVA-TRISP collaboration C Traenka, J Lorscheider, C Hametner, P Baumgartner, J Gralla, ... Journal of stroke 25 (2), 272-281, 2023 | 2 | 2023 |
| Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis S Meier, EAJ Willemse, S Schaedelin, J Oechtering, J Lorscheider, ... JAMA neurology 80 (3), 287-297, 2023 | 57 | 2023 |
| Synthesizing cross‐design evidence and cross‐format data using network meta‐regression T Hamza, K Chalkou, F Pellegrini, J Kuhle, P Benkert, J Lorscheider, ... Research Synthesis Methods 14 (2), 283-300, 2023 | 7 | 2023 |
| Recurrent disability progression endpoints in multiple sclerosis clinical trials A Bühler, M Wolbers, F Model, Q Wang, S Belachew, M Manfrini, ... Multiple Sclerosis Journal 29 (1), 130-139, 2023 | 1 | 2023 |
| Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network A Signori, J Lorscheider, S Vukusic, M Trojano, P Iaffaldano, J Hillert, ... Journal of Neurology, Neurosurgery & Psychiatry 94 (1), 23-30, 2023 | 10 | 2023 |
| Reliability and acceptance of dreaMS, a software application for people with multiple sclerosis: a feasibility study T Woelfle, S Pless, O Reyes, A Wiencierz, A Feinstein, P Calabrese, ... Journal of Neurology 270 (1), 262-271, 2023 | 16 | 2023 |
| Increased serum glial fibrillary acidic protein (GFAP) levels predict disease progression in B cell depleted patients with progressive MS P Benkert, A Maceski, J Lorscheider, S Schaedelin, EAJ Willemse, ... MULTIPLE SCLEROSIS JOURNAL 28 (3_ SUPPL), 592-593, 2022 | | 2022 |
| Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis A Cagol, S Schaedelin, M Barakovic, P Benkert, RA Todea, ... JAMA neurology 79 (7), 682-692, 2022 | 67 | 2022 |
